边缘缩小对接受图像引导容积旋转调强放疗的头颈癌患者结局和毒性的影响
2013至2016年间,206例连续患者接受5 mm的CTV-PTV边缘放疗,随后208例接受3 mm边缘。所有患者均接受每日CBCT引导的VMAT。3 mm组急性3级毒性、3级口腔黏膜炎和3级吞咽困难(依赖喂养管)均显著低于5 mm组,且未影响肿瘤结局。
要点
- 3 mm组急性3级毒性发生率为53.8%,显著低于5 mm组的65%(p=0.032)。
- 3 mm组急性3级口腔黏膜炎为30.8%,显著低于5 mm组的42.2%(p=0.008)。
- 放疗后3个月持续依赖喂养管的发生率3 mm组为11.1%,5 mm组为20.4%(p=0.012)。
核心结论
- 将CTV-PTV边缘从5 mm缩小至3 mm并结合每日CBCT引导的VMAT,降低了放疗相关毒性的严重程度、发生频率和持续时间,且未危及肿瘤结局。
研究设计与样本
- 2013年至2016年间,206例连续患者接受5 mm的CTV-PTV边缘放疗,随后208例患者接受3 mm边缘放疗。
- 所有患者均接受每日锥形束CT(CBCT)图像引导的容积旋转调强放疗(VMAT)。
主要发现
- 3 mm组急性3级毒性发生率为53.8%,5 mm组为65%(p=0.032)。
- 3 mm组急性3级口腔黏膜炎发生率为30.8%,5 mm组为42.2%(p=0.008)。
- 3 mm组急性3级吞咽困难(依赖喂养管)发生率为22.1%,5 mm组为33.5%(p=0.026)。
- 放疗后3个月持续依赖喂养管的发生率3 mm组为11.1%,5 mm组为20.4%(p=0.012)。
- 2年晚期≥2级口干发生率3 mm组为15.8%,5 mm组为19.4%(p=0.8);2年局部区域控制率3 mm组为79.9%,5 mm组为79.2%(p=1.0);无病生存率3 mm组为71.5%,5 mm组为72.7%(p=0.6);总生存率3 mm组为75.2%,5 mm组为75.1%(p=0.9)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In recent decades, outcomes of patients with head and neck cancer (HNC) have improved as a result of implementing several strategies, such as chemoradiation. However, these improvements were achieved at the cost of increased toxicity. One way to reduce radiation-related toxicity is by reducing the margins. MATERIALS AND METHODS: Between 2013 and 2016, 206 consecutive patients were treated with CTV-PTV margin of 5 mm and subsequently 208 patients with 3 mm margin. This study evaluates the impact of reducing clinical target volume (CTV) to planning target volume (PTV) margin on outcome and toxicity. RESULTS: All patients were treated with volumetric modulated arc therapy (VMAT) with daily-image guidance using cone-beam CT (CBCT). Overall acute grade 3 toxicity was significantly lower in 3 mm-group, compared to 5 mm-group (53.8% vs. 65%, respectively, p = 0.032). The same was true for acute grade 3 mucositis (30.8% vs. 42.2%, p = 0.008) and for acute grade 3 dysphagia (feeding tube-dependence) (22.1% vs. 33.5%, p = 0.026). The incidence of ongoing feeding tube-dependence after 3 months of radiotherapy was 11.1% and 20.4%, respectively (p = 0.012). The 2-year incidence of late grade ≥2 xerostomia was 15.8% and 19.4% (p = 0.8). The 2-year loco-regional control rates of patients treated in 3 mm and 5 mm-groups were 79.9% and 79.2% (p = 1.0). The figures for disease-free survival were 71.5% and 72.7 (p = 0.6) and for overall survival were 75.2% and 75.1% (p = 0.9). CONCLUSION: Reducing the CTV-PTV margin from 5 to 3 mm combined with daily CBCT-guided VMAT reduced the severity, frequency, and duration of radiation-related toxicity without jeopardizing outcome.
引用
- Navran A, Heemsbergen W, Janssen T, et al. The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT). Radiother Oncol. 2018. PMID: 30005953. doi:10.1016/j.radonc.2018.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。